[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.236.190.216. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
May 2013

Successful Treatment With Vemurafenib in BRAF V600K–Positive Cerebral Melanoma Metastasis

Author Affiliations

Author Affiliations: Departments of Dermatology (Drs Forschner, Bauer, Garbe, and Meier and Ms Niessner) and Neuroradiology (Dr Bender), Eberhard-Karls University of Tuebingen, Tuebingen, Germany.

JAMA Dermatol. 2013;149(5):642-644. doi:10.1001/jamadermatol.2013.372

More than 90% of the BRAF mutations in melanoma are identified at codon 600, and about 80% of these are BRAF V600E mutations. The second most common mutation is the BRAF V600K mutation, representing 14% to 28% of BRAF mutations in melanoma.1 Vemurafenib treatment for metastatic melanoma has been extensively studied in patients harboring the BRAF V600E mutation. There are rare data concerning the BRAF V600K mutation.

×